Potential Jurisdictional Change Draws Protest From Wound Product Firms
This article was originally published in The Gray Sheet
Executive Summary
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis
You may also be interested in...
Wound-Healing Combo Product Jurisdiction Should Be Clarified – Ex-FDAer
The regulatory pathway for wound-healing combination products should be elucidated because they increasingly are assigned to CBER and not the device center, according to The Biologics Consulting Group Senior Consultant Darin Weber, PhD
Wound-Healing Combo Product Jurisdiction Should Be Clarified – Ex-FDAer
The regulatory pathway for wound-healing combination products should be elucidated because they increasingly are assigned to CBER and not the device center, according to The Biologics Consulting Group Senior Consultant Darin Weber, PhD
Primary Mode of Action Is A Primary Focus Of Combo Products Hearing
FDA's recent announcement that it is reconsidering jurisdiction for wound products indicates a problematic shift in the agency's interpretation of "primary mode of action," AdvaMed maintained at a June 24 public hearing to discuss the regulation of combination products containing live cellular components